Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

This work was sponsored by Alkermes, Inc. INTRODUCTION: Atypical long-acting injectable (aLAI) antipsychotics are effective treatment options but may be underutilized in the treatment of schizophrenia. OASIS (NCT03919994) was a prospective, observational study assessing real-world outcomes associated with aLAI antipsychotics. This presentation reviews key clinician- and patient-reported outcomes from OASIS. METHODS AND DESIGN: Adults (≥18 years) with schizophrenia who newly initiated 1 of 4 aLAI antipsychotics (aripiprazole lauroxil, aripiprazole monohydrate, paliperidone palmitate, or risperidone microspheres) were eligible. Patients were evaluated up to 12 months thereafter according to routine follow-up. Overall illness severity was evaluated using the Clinical Global Impressions–Severity (CGI-S) score. Individual symptom domains were assessed using the Clinician-Rated Dimensions of Psychosis Severity Scale (CRDPSS); side effects of antipsychotics were assessed using the patient-reported Glasgow Antipsychotic Side-Effect Scale (GASS) total score. RESULTS: Patients with schizophrenia (Nf277) had moderate illness severity at baseline according to the CGI-S (mean 4.2 [SD=1.1]). Individual symptoms were mild on CRDPSS (eg, delusions score 2.0 [SD=1.3]; hallucinations 1.9 [SD=1.4]; negative symptoms, 1.6 [SD=1.3]). The average baseline GASS total score was 10.7 (SD=10.3), which indicated absent or mild side effects. After initiating aLAI antipsychotic treatment, overall symptoms remained stable according to CGI-S and CRDPSS scores among patients with available data. On average, patient-reported antipsychotic side effects were absent or mild over follow-up assessed by GASS total score. CONCLUSION: Among patients with available data, results suggest that those with schizophrenia who initiated aLAI antipsychotic treatment had stable schizophrenia symptoms with mostly absent or mild patient-reported antipsychotic side effects over 12 months of potential follow-up.